Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. Click here to find out why CHRS ...
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback